Getinge (GETI B)
Free
No email, no account, no signup.
Pulling latest news for Getinge…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
HOLD
Sentiment
5/10
Risk
6/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Getinge AB is a Swedish medtech company providing equipment and solutions to hospitals and life science customers globally. The company is profitable with improving underlying margins, but reported results are affected by FX/tariffs and recurring regulatory/quality risks (especially in the US).
Exchange
Nasdaq Stockholm
Sector
Medical technology and hospital equipment
Market Cap
$5.6B
Market sentiment
Sentiment is **neutral to slightly negative**, driven by FX/tariffs and regulatory risk, with some stabilization from cash flow, dividends, and signs of margin improvement.
Why HOLD ?
- **Hold** given profitability, positive cash flow, and dividend support.
- Upside exists via **margin expansion** and segment recovery, but **FDA/compliance** and growth uncertainty keep the risk premium elevated.
- It is reasonable to wait for **Q1 2026** confirmation and any regulatory updates.
- Hold the current position; consider waiting to add until after the Q1 report and clearer regulatory status. If headwinds intensify, consider trimming 10–20%.
Recent News
- Since the last analysis, Getinge released Q1 2026 results (Apr 21) and held its AGM. Q1 delivered organic sales growth of +0.8% and organic order growth of +3.9% (9th consecutive quarter of order growth), while adjusted EBITA of SEK 824m and an 11.1% margin were negatively impacted by FX (weaker USD) and US import tariffs. Free cash flow improved sharply (SEK 842m) and full-year guidance of 3–5% organic sales growth was reiterated. The dividend was confirmed at SEK 4.75/share (record date Apr 23, payment from Apr 28). Late in the quarter, the company also communicated EU regulatory progress (CE mark for Cardiohelp II and EU MDR approval for Intergard Synergy).
Bull case
- **Dividend** (SEK 4.75) may support the stock around the ex-date.
- Underlying **margin improvement** (ex FX/tariffs) could show in Q1.
Unlock to read more →
Bear case
- Continued **FX and tariff headwinds** may pressure reported numbers.
Unlock to read more →
Catalysts
16 Jul 2026 — Q2/H1 2026 report
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Getinge – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.